4497nok
4,6 %
Date:2026-02-17Time:10:31:14Latest report:Q2-2024List:Oslo BorsTicker:ONCIN
Market Cap:201 mnokEnterprise Value:136 mnokNet Sales:5,41 mnokEarnings:-107,6 mnokEmployees:0ISIN:NO0013711713

Ratios

10-year key figure history for Oncoinvent turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Oncoinvent with index and moving average MA50 and MA200.

Stockprice:44,97
MA50:46,56
MA200:104,17
Price/MA200:-56,8 %
RSI (14):53,8
Price/MA50:-3,4 %

Description

Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.

Biotechnology